健择联合顺铂治疗晚期非小细胞肺癌84例疗效观察  

Clinical Observation of Gemcitabine Plus Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：顾兰兵 卢勇[1] 

机构地区：[1]江苏省大丰市第三人民医院内科,江苏大丰224100

出　　处：《河北医学》2013年第2期224-226,共3页Hebei Medicine

摘　　要：目的:观察健择联合顺铂化疗方案治疗晚期非小细胞肺癌的疗效及毒副作用。方法:自2006年5月至2009年10月,采用健择联合顺铂治疗84例晚期非小细胞肺癌,健择1000mg/m2,静滴,第1,8天;顺铂40 mg/m2,静滴,第1-3天,21d为1个周期,治疗2-3个周期。结果:84例患者当中,完全缓解2例,部分缓解36例,总有效率45.24%。其中Ⅲb期患者有效率51.85%,Ⅳ期患者有效率33.33%;鳞癌患者总有效率55.56%,腺癌患者有效率37.5%;初治患者有效率53.57%,复治患者有效率28.57%。主要毒副作用为Ⅱ-Ⅲ度骨髓抑制及胃肠道反应,无明显出血及明显肝肾功能损害。结论:健择联合顺铂化疗方案治疗晚期非小细胞肺癌有较好疗效,耐受性较好。Objective： To observe and evaluate the therapeutic effects and toxicity reaction of gemcit- abine plus cisplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Method： Enrolled from May 2006 to Oct. 2009, 84 patients with advanced NSCLC were treated with gemcitabine plus cisplatin therapy. Gemcitabine 1000mg/m2 by intravenous infusion on 1st and 8th day, and cisplatin 40mg/m2 by in- travenous infusion on 1-3th day in a 21-day cycle, and every patient was treated 2-3 cycles. Result： Of the 84 patients, 2 cases got complete response, 36 cases got partial response, with an overall response rate of 45.24%. And the response rate was 51.85% in patients of IIIb stage, 33.33% in patients of IV stage; it was 55.56% in patients with squamous-celled NSCLC and 37.5% in patients with adenocarcinoma; it was 53.57% in the initial patients and 28.57% in the retreated patients. The main toxicities were bone marrow suppression and gastrointestinal tract reaction, and no bleeding or hepatic/renal function impairment was ob- served. Conclusion： The combination of gemcitabine and cisplatin is feasible, well-tolerated and effective scheme in advanced NSCLC patients.

关 键 词：健择 顺铂 晚期非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤]